Responses
E-Poster viewings
Ovarian Cancer
IGCS19-0435
312 Aries: a phase 2, open-label study to evaluate rucaparib (PARP inhibitor) in combination with nivolumab (Anti-PD-1 Antibody) in patients with ovarian or urothelial cancer (UC)
Compose a Response to This Article
Other responses
No responses have been published for this article.